Prediction
## Modified Eligibility Criteria for Clinical Trial Version 10
**Inclusion Criteria:**
* **Age:** Adult male, aged 18 to 65 years inclusive.
* **BMI:** BMI > 30 kg/m2
* **HbA1c:** HbA1c ≤ 10.5% at Screening.
* **Type 2 Diabetes:**
* HbA1c ≤ 10.5% at Screening.
* Anti-diabetic medication regimen (excluding insulin) has been stable for ≥ 8 weeks before the first Screening visit.
* **Other Exclusion Criteria:**
* History of monoclonal antibodies, insulin, or other medications known to affect sex hormone production within the 4 weeks prior to the first Screening Visit.
* Weight loss or weight gain (gain or loss > 5% body weight) OR weight reduction surgery or procedure within the 3 months prior to first Screening Visit.
* Participation in any clinical trial using clinical investigational product intervention within 3 months before first Screening Visit or 5 half-lives of investigational product administration, whichever is longer.
* Medical history of Long QT syndrome.
* History of thromboembolic disease.
* Grade ≥3 lower extremity oedema.
* Use of cardiac pacemaker or other medical electronic devices that can be affected by bioimpedance assessment.
* Medical diagnosis of any of the following cardiovascular conditions within the 6 months prior to first Screening Visit:
* Myocardial infarction or unstable angina.
* Coronary artery bypass surgery, balloon angioplasty, percutaneous coronary intervention or carotid revascularisation procedure.
* Uncontrolled hypertension within the 3 months prior to first Screening Visit.
* Significant cardiac arrhythmia (as determined by the investigator).
* Endovascular procedure or surgical intervention for peripheral vascular disease within the 3 months prior to first Screening Visit.
* Advanced ischemic heart disease.
**Note:** The specific inclusion and exclusion criteria may vary depending on the version of the protocol.